Arvind Utchanah
Director of Finance/CFO chez KNIGHT THERAPEUTICS INC.
Fortune : 153 413 $ au 31/03/2024
Profil
Arvind Utchanah is currently the Chief Financial Officer at Knight Therapeutics, Inc. He previously worked as the Director-Finance, Accounting & Financial Planning at Paladin Labs, Inc. from 2012 to 2016.
Mr. Utchanah has an undergraduate degree from McGill University and a graduate degree from Concordia University.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 12/04/2024 | 39 136 ( 0,04% ) | 153 413 $ | 31/03/2024 |
Postes actifs de Arvind Utchanah
| Sociétés | Poste | Début |
|---|---|---|
| KNIGHT THERAPEUTICS INC. | Director of Finance/CFO | 30/03/2020 |
Anciens postes connus de Arvind Utchanah
| Sociétés | Poste | Fin |
|---|---|---|
| PALADIN LABS INC. | Director of Finance/CFO | 01/06/2016 |
Formation de Arvind Utchanah
| McGill University | Undergraduate Degree |
| Concordia University | Graduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| KNIGHT THERAPEUTICS INC. | Health Technology |
| Entreprise privées | 1 |
|---|---|
Paladin Labs, Inc.
 Paladin Labs, Inc. Pharmaceuticals: MajorHealth Technology Paladin Labs Inc. operates as pharmaceutical company. It engages in developing, acquiring, in-licensing, marketing, and distributing innovative pharmaceutical products in Canada and internationally. The firm's products include Abstral, GlucaGen, Metadol, Plan B, Pennsaid, Seasonale, Testim, Twinject, Dexedrin, Tridural, and Trelstar. The company was founded by Jonathan Ross Goodman and Mark Beaudet on February 25, 1983 and is headquartered in Montreal, Canada. | Health Technology |
